KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)DivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Gains from Sales and Divestitures (2010 - 2011)

Pfizer (PFE) reported Gains from Sales and Divestitures of $13.3 million for Q4 2011, up 17126.92% year-over-year from N/an in Q4 2010, and up 17126.92% on a QoQ basis from -$78000.0 in Q4 2010.

Pfizer (PFE) has 2 years of Gains from Sales and Divestitures data on file, last reported at $13.3 million in Q4 2011.

  • Quarterly Gains from Sales and Divestitures rose 17126.92% year-over-year to $13.3 million in Q4 2011, while the trailing twelve-month figure through Dec 2011 was $13.3 million (up 17126.92% YoY) and the FY2011 annual result came in at $13.3 million, up 17126.92% from the prior year.
  • Gains from Sales and Divestitures rose to $13.3 million in Q4 2011 per PFE's latest filing, from -$78000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $13.3 million in Q4 2011 and bottomed at -$78000.0 in Q4 2010.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2011 13.28 Mn
Dec 31, 2011 13.28 Mn
Dec 31, 2010 -78,000.00
Dec 31, 2010 -78,000.00